Boston NamingTest performance in mild cognitive impairment: a meta-analysis

波士顿命名测试在轻度认知障碍患者中的表现:一项荟萃分析

阅读:1

Abstract

BACKGROUND: Naming impairment is frequently observed in cognitive decline, but evidence in mild cognitive impairment (MCI) remains inconsistent. This study aimed to systematically evaluate naming ability in individuals with MCI. METHODS: A systematic search of PubMed, Web of Science, EMBASE, and Cochrane Library (2015–2025) identified 20 cross-sectional studies comparing Boston Naming Test (BNT) performance between MCI patients and healthy controls. To ensure methodological comparability, only studies using the BNT were included. Standardized mean differences (SMDs) were calculated using random-effects models. Heterogeneity, publication bias, and potential moderators (age, sex, education, global cognition) were assessed. RESULTS: The meta-analysis included 1,306 MCI patients and 3,877 controls. MCI patients performed significantly worse on naming tasks than controls (SMD = -0.841, 95% CI: -1.001 to -0.675; p < 0.001), with consistent findings across BNT versions. Meta-regression revealed no moderating effects of age, sex, or education, while global cognitive function significantly affected naming performance. Substantial heterogeneity was observed. CONCLUSION: Reduced performance on the Boston Naming Test is common in individuals with MCI and appears to be partially related to global cognitive status rather than demographic factors. Future studies should explore subtype-specific patterns and longitudinal associations to clarify the clinical significance of naming impairments in MCI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-026-04773-0.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。